Use of ex vivo binding to estimate brain penetration and central activity of CCK-B antagonists.
Patel
S
S
Merck Sharp & Dohme Research Laboratories, Department of Biochemistry, Harlow, Essex, England.
Chapman
K L
KL
Smith
A J
AJ
Heald
A
A
Freedman
S B
SB
D000818:Animals; D001569:Benzodiazepines / Q000378:metabolism* / Q000494:pharmacology; D001570:Benzodiazepinones / Q000378:metabolism* / Q000494:pharmacology; D001921:Brain / Q000378:metabolism*; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology*; D007276:Injections, Intraventricular; D007444:Inulin / Q000378:metabolism; D007457:Iodine Radioisotopes; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D010671:Phenylurea Compounds; D011869:Radioligand Assay; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013777:Tetrazoles / Q000378:metabolism* / Q000494:pharmacology
D001570:Benzodiazepinones; D007211:Indoles; D007457:Iodine Radioisotopes; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; D013777:Tetrazoles; D001569:Benzodiazepines; C065599:PD 134308; C087236:L 368935; C058121:L 365260; D008536:Meglumine; D007444:Inulin